Clinical Trials Using Ipilimumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ipilimumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 164

  • Panitumumab, Nivolumab, and Ipilimumab in Treating Patients with KRAS, NRAS, or BRAF Wild-Type MSS Refractory Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well panitumumab, nivolumab, and ipilimumab work in treating patients with KRAS, NRAS, or BRAF wild-type microsatellite stable (MSS) colorectal cancer that does not respond to treatment (refractory), has spread to other places in the body (metastatic), and cannot be removed by surgery (unresectable). Monoclonal antibodies, such as panitumumab, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 4 locations

  • Pepinemab with or without Ipilimumab or Nivolumab in Treating Patients with Stage I-III Pancreatic Cancer That Can Be Removed by Surgery or Stage IV Colorectal Cancer with Liver Metastasis That Can Be Removed by Surgery

    This phase I trial studies how well pepinemab with or without ipilimumab or nivolumab works in treating patients with stage I-III pancreatic cancer that can be removed by surgery or stage IV colorectal cancer that has spread to the liver (liver metastasis) and can be removed by surgery. Monoclonal antibodies, such as pepinemab, may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 4 locations

  • Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

    This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg / kg) and Nivolumab (3 mg / kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then nivolumab 480 mg will be administered Day 1 of a 28-day cycle for Cycles 5-15 (maximum of 15) or until disease recurrence or intolerance before completion of 15 cycles.
    Location: 4 locations

  • Cabozantinib S-malate and Nivolumab with or without Ipilimumab in Treating Patients with Metastatic Genitourinary Tumors

    This phase I trial studies the side effects and best doses of cabozantinib s-malate and nivolumab with or without ipilimumab in treating patients with genitourinary (genital and urinary organ) tumors that have spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving cabozantinib s-malate and nivolumab alone or with ipilimumab works better in treating patients with genitourinary tumors.
    Location: 5 locations

  • Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer

    This phase II trial investigates how well nivolumab and ipilimumab work in treating patients with INI-1 negative cancer that has come back (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Cabozantinib, Nivolumab, and Ipilimumab for the Treatment of Metastatic Non-clear Cell Renal Cell Cancer

    This phase II trial studies the effect of cabozantinib, nivolumab, and ipilimumab for the treatment of non-clear cell renal cell cancer (kidney cancer) that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. The purpose of this trial is to assess whether cabozantinib, nivolumab, and ipilimumab in combination are safe and effective (how well the drug works) in slowing down the growth of kidney cancer.
    Location: 3 locations

  • UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

    UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic melanoma. This study will explore the Efficacy and Safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab.
    Location: 4 locations

  • Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Unresectable Stage IIIb-IV Melanoma

    This phase II trial studies the side effects and how well tocilizumab, ipilimumab, and nivolumab work in treating patients with stage IIIb-IV melanoma that cannot be removed by surgery (unresectable). Tocilizumab is a monoclonal antibody that works by blocking the receptor of the interleukin-6 (IL-6) protein in the body. IL-6 is a protein thought to help cancer cells grow and survive against the body’s defense mechanisms. Tocilizumab blocks the receptor of the IL-6 protein, which prevents the IL-6 protein from functioning. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tocilizumab, ipilimumab, and nivolumab may work better in treating patients with melanoma compared to ipilimumab and nivolumab alone.
    Location: 3 locations

  • An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

    The main purpose of this study is to characterize the safety, tolerability, dose limiting toxicities, best route of administration, maximum tolerated dose, maximum administered dose, or alternative dose of BMS-986301 alone or in combination with nivolumab and ipilimumab in participants with cancers that have failed to respond to T cell checkpoint inhibiting antibodies.
    Location: 3 locations

  • Nivolumab with or without Ipilimumab before Surgery for the Treatment of Resectable Stage I-III Malignant Pleural Mesothelioma

    This phase II trial studies the side effects of nivolumab with or without ipilimumab before surgery in treating patients with stage I-III malignant pleural mesothelioma that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

    A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.
    Location: 3 locations

  • Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)

    This study will compare the clinical activity of novel regimens (in combination or as single agents) to standard of care in participants with relapsed / refractory advanced NSCLC. The study will be conducted in two parts; Part 1 is an optional, non-randomized part based on safety and pharmacokinetics / pharmacodynamics (PK / PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II study comparing the efficacy and safety of these novel regimens with SoC.
    Location: 5 locations

  • Radiation Therapy, Chemotherapy, Ipilimumab, and Nivolumab in Treating Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

    This phase I / II trial studies the side effects and how well ipilimumab with radiation therapy and chemotherapy followed by nivolumab works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, carboplatin, and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ipilimumab with radiation therapy and chemotherapy followed by nivolumab may work better in treating patients with non-small cell lung cancer.
    Location: 3 locations

  • Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer

    This is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ≥ 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, and participants who have a tumor with < 15% CD8 cells (classified as CD8 low) will receive ipilimumab in combination with nivolumab.
    Location: 6 locations

  • An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

    The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.
    Location: 3 locations

  • An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
    Location: 3 locations

  • Nivolumab with or without Ipilimumab in Treating Patients with Recurrent High-Grade Meningioma

    This phase II trial studies how well nivolumab with or without ipilimumab work in treating patients with high-grade meningioma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab and ipilimumab will work better in treating patients with meningioma than nivolumab alone.
    Location: 3 locations

  • Nivolumab with or without Ipilimumab in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

    This phase II trial studies the side effects of nivolumab with or without ipilimumab and to see how well it works in treating patients with stage IB-IIIA non-small cell lung cancer that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Nivolumab Alone or in Combination with Ipilimumab before Surgery for the Treatment of Surgically Accessible Relapsed IDH-Wildtype Glioblastoma

    This phase Ib trial identifies the side effects and evaluates the effect of nivolumab alone or in combination with ipilimumab before surgery in treating patients with IDH-wildtype glioblastoma that has come back (relapsed) and can be removed by surgery. Nivolumab and ipilimumab are antibodies (types of human protein) that work to stop tumor cells from growing and multiplying by immunotherapy. Immunotherapy uses the body’s own immune system to work against tumor cells. Giving nivolumab with or without ipilimumab before surgery may make the tumor smaller. Giving nivolumab alone or in combination with ipilimumab after surgery may kill any remaining tumor cells.
    Location: 2 locations

  • Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer

    This phase I trial investigates the feasibility and safety of an implantable microdevice for the evaluation of drug response in patients with prostate cancer. Implanting and retrieving a microdevice that releases up to 20 drugs directly within the prostate cancer lesion may help to evaluate the effectiveness of several approved cancer drugs against prostate cancer. Once optimized, the implantable microdevice may be able to predict the efficacy of specific drugs for each patient’s tumor and inform therapeutic decision-making.
    Location: 2 locations

  • Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab with or without Ipilimumab) in Patients with Advanced Solid Cancers That Have Changes in the following Genes: PIK3CA and PTEN

    This phase I / II trial studies the side effects and best dose of copanlisib when given together with nivolumab and ipilimumab and to see how well they work in treating patients with solid cancers that have spread to other places in the body (advanced) and have changes in PIK3CA and PTEN genes. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of copanlisib to usual chemotherapy may work better in treating patients with solid cancers compared to usual chemotherapy alone.
    Location: 2 locations

  • A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

    The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
    Location: 3 locations

  • T Cell-Depleted Donor Lymphocyte Infusion and Ipilimumab in Treating Patients with Myeloid Disease Relapse after Donor Stem Cell Transplant

    This phase I trial studies the side effects and best dose of T cell-depleted donor lymphocyte infusion and ipilimumab in treating patients with acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, chronic myelomonocytic leukemia, or myelofibrosis that has come back after a donor stem cell transplant. Previously, patients who have relapsed after a donor stem cell transplant have been given infusions of donor white blood cells called donor lymphocyte infusions (DLI) as a way to boost their donor’s immune function and fight the cancer. This immune function can be suppressed by natural anti-inflammatory immune cells (T cells) that are present in the DLI product. Depleting the number of T cells in the DLI product may work better in fighting the cancer. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial determines the highest dose of ipilimumab that can be given safely in several courses and whether ipilimumab may help the donor white blood cells kill the cancer cells.
    Location: 2 locations

  • Pepinemab with or without Ipilimumab and / or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer

    This phase I trial studies how well pepinemab with or without ipilimumab and / or nivolumab work in treating participants with stage I-IVA head and neck squamous cell cancer. Immunotherapy with monoclonal antibodies, such as pepinemab, ipilimumab, and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 2 locations

  • A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

    The purpose of this study is to determine whether nivolumab plus ipilimumab or nivolumab alone is effective and safe in the treatment of solid tumors with High Tumor Mutational Burden (TMB-H)
    Location: 3 locations